Deal Snapshot: Ipsen has entered into a global licensing agreement with Foreseen Biotechnology potentially worth up to $1.03bn, its second antibody-drug conjugate tie-up this year, a few months after unveiling a partnership with Sutro.
Who:Ipsen SA and China's Foreseen Biotechnology.
What: A global licensing agreement which will see the French firm develop and commercialize FS001, an antibody-drug conjugate (ADC) with...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.
